Literature DB >> 14760961

Therapy related acute myeloblastic leukaemia after mitoxantrone treatment in a patient with multiple sclerosis.

B Delisse, J de Seze, A Mackowiak, J B N'Kendjuo, A Verier, O Derepeer, C Boisselier, P Devos, P Hautecoeur, P Vermersch.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 14760961     DOI： 10.1191/1352458504ms977xx

Source DB:  PubMed          Journal:  Mult Scler        ISSN： 1352-4585            Impact factor:   6.312


× No keyword cloud information.
  6 in total

Review 1.  Escalating immunotherapy of multiple sclerosis--new aspects and practical application.

Authors:  P Rieckmann; K V Toyka; C Bassetti; K Beer; S Beer; U Buettner; M Chofflon; M Götschi-Fuchs; K Hess; L Kappos; J Kesselring; N Goebels; H-P Ludin; H Mattle; M Schluep; C Vaney; U Baumhackl; T Berger; F Deisenhammer; F Fazekas; M Freimüller; H Kollegger; W Kristoferitsch; H Lassmann; H Markut; S Strasser-Fuchs; K Vass; H Altenkirch; S Bamborschke; K Baum; R Benecke; W Brück; D Dommasch; W G Elias; A Gass; W Gehlen; J Haas; G Haferkamp; F Hanefeld; H-P Hartung; C Heesen; F Heidenreich; R Heitmann; B Hemmer; T Hense; R Hohlfeld; R W C Janzen; G Japp; S Jung; E Jügelt; J Koehler; W Kölmel; N König; K Lowitzsch; U Manegold; A Melms; J Mertin; P Oschmann; H-F Petereit; M Pette; D Pöhlau; D Pohl; S Poser; M Sailer; S Schmidt; G Schock; M Schulz; S Schwarz; D Seidel; N Sommer; M Stangel; E Stark; A Steinbrecher; H Tumani; R Voltz; F Weber; W Weinrich; R Weissert; H Wiendl; H Wiethölter; U Wildemann; U K Zettl; F Zipp; R Zschenderlein; G Izquierdo; A Kirjazovas; L Packauskas; D Miller; B Koncan Vracko; A Millers; A Orologas; M Panellus; C J M Sindic; M Bratic; A Svraka; N R Vella; Z Stelmasiak; K Selmaj; H Bartosik-Psujik; K Mitosek-Szewczyk; E Belniak; A Mochecka; A Bayas; A Chan; P Flachenecker; R Gold; B Kallmann; V Leussink; M Mäurer; K Ruprecht; G Stoll; F X Weilbach
Journal:  J Neurol       Date:  2004-11       Impact factor: 4.849

Review 2.  Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

Authors:  James J Marriott; Janis M Miyasaki; Gary Gronseth; Paul W O'Connor
Journal:  Neurology       Date:  2010-05-04       Impact factor: 9.910

Review 3.  Acute myeloid leukemia developing in patients with autoimmune diseases.

Authors:  Safaa M Ramadan; Tamer M Fouad; Valentina Summa; Syed Kh Hasan; Francesco Lo-Coco
Journal:  Haematologica       Date:  2011-12-16       Impact factor: 9.941

4.  Acute myeloid leukemia induced by mitoxantrone treatment for aggressive multiple sclerosis.

Authors:  Marco Capobianco; Simona Malucchi; Stefano Ulisciani; Carmen Fava; Giovanna Rege Cambrin; Luigina Avonto; Giuseppe Saglio; Antonio Bertolotto
Journal:  Neurol Sci       Date:  2008-07-09       Impact factor: 3.307

5.  Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis.

Authors:  Syed Khizer Hasan; Ashley N Mays; Tiziana Ottone; Antonio Ledda; Giorgio La Nasa; Chiara Cattaneo; Erika Borlenghi; Lorella Melillo; Enrico Montefusco; José Cervera; Christopher Stephen; Gnanam Satchi; Anne Lennard; Marta Libura; Jo Ann W Byl; Neil Osheroff; Sergio Amadori; Carolyn A Felix; Maria Teresa Voso; Wolfgang R Sperr; Jordi Esteve; Miguel A Sanz; David Grimwade; Francesco Lo-Coco
Journal:  Blood       Date:  2008-07-23       Impact factor: 22.113

6.  Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study.

Authors:  Victor M Rivera; Douglas R Jeffery; Bianca Weinstock-Guttman; Daena Bock; Fernando Dangond
Journal:  BMC Neurol       Date:  2013-07-11       Impact factor: 2.474
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.